Evidence map›Paper›PMID 39230655›Full record

ArticleNeurotoxicity research2024

Pharmacology of Adenosine A

Tsung-Ming Shih, Crystal Munoz, Cindy Acon-Chen, Zora-Maya Keith

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurotoxicity research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Neurocognitive and neurobiological effects of low dose organophosphate exposure.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tsung-Ming ShihNeuroscience Department, Medical Toxicology Research Division, U.S. Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD, 21010-5400, USA. tsungming.a.shih.civ@health.mil.ORCID http://orcid.org/0000-0002-5252-9198
Crystal MunozNeuroscience Department, Medical Toxicology Research Division, U.S. Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD, 21010-5400, USA.ORCID http://orcid.org/0009-0007-9253-8738
Cindy Acon-ChenNeuroscience Department, Medical Toxicology Research Division, U.S. Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD, 21010-5400, USA.
Zora-Maya KeithNeuroscience Department, Medical Toxicology Research Division, U.S. Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD, 21010-5400, USA.

Funding

National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH) Interagency Agreement number AOD22011-001-00000
6 · The paper itself

Abstract

Recently a novel genetically modified mouse strain with serum carboxylesterase knocked-out and the human acetylcholinesterase gene knocked-in (KIKO) was created to simulate human responses to nerve agent (NA) exposure and its standard medical treatment. A

Indexed as

AcetylcholinesteraseAdenosine A1 Receptor AgonistsDisease Models, AnimalSeizuresSomanAdenosineAnimalsAnticonvulsantsElectroencephalographyHumansMaleMiceMice, KnockoutAcetylcholinesteraseAdenosineAdenosine A1 Receptor AgonistsAnticonvulsantsSomanA1 adenosine receptor agonistAnticonvulsantElectroencephalographic activityGenetically modified mouse strainNeuroprotectantSoman

Identifiers

PMID39230655
PMCPMC11374867

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.